Justice also said Schering-Plough underpaid rebates for the stomach ailment drug K-Dur (a potassium supplement). The Justice Department also alleged that Schering-Plough defrauded Medicaid of US$4.3 million in the late 1990s by overcharging the agency, which provides health insurance to the poor and disabled, for the systemic antihistamine, Claritin RediTabs. According to the Justice Department, Schering-Plough paid doctors honoraria, directed prestigious and lucrative research grants their way, placed them on well-paying medical advisory boards and treated them to lavish dinners and other forms of entertainment in return for prescribing the drugs for the non-approved (off-label) usages. The allegations involved temozolomide (Temodar), which the company promoted for use in treating brain tumours and metastatic cancer, and Interferon alfa-2a (Intron A), for use in superficial bladder cancer and hepatitis C.Īlthough it's illegal for pharmaceuticals to promote drugs for non FDA-approved treatments, doctors have no such restrictions. One of the largest health care fines ever meted out by the Justice Department, it brings to US$1.3 billion the total paid by Schering-Plough as a result of the settlements.Īccording to the government, Schering-Plough engaged in illegal sales and marketing practices involving several cancer drugs by promoting their use for treatments not government-approved at the time. The case marks the third time in the last 5 years that the company, which has annual sales of approximately US$10 billion, has reached a multi-million settlement with the government. The agreement was reached in late summer with the US Justice Department, which also alleged the New Jersey–based company had defrauded Medicaid, the government health care program. Michael Schäffer, CEO of CRELUX.Schering-Plough Corp., the US pharmaceutical manufacturer perhaps best known for its anti-allergy medication Claritin, has agreed to pay US$435 million in fines to settle criminal and civil charges that it illegally promoted several drugs. ![]() Being so far mainly active for US-based Pharma companies this further validates our business model and helps us tremendously to strengthen our position in Europe” said Dr. “We are especially delighted that the just recently established German big pharma company Bayer Schering Pharma has picked CRELUX for this high value service project. The company’s structural biology platform encompasses all steps from target cloning and expression up to high throughput protein crystallization and in-house x-ray crystallography. Under the agreement CRELUX receives fixed and success based payments on a fee-forservice basis.ĬRELUX has used its structural biology platform to solve more than 200 crystal and co-crystal structures in contract research agreements for pharma and biotech companies. The work will include all steps from construct design up to a number of complex structures with small molecule inhibitors provided by Bayer Schering Pharma AG. Under the agreement CRELUX will provide structural biology services on three undisclosed target proteins. ![]() CRELUX has announced that it has been selected by Bayer Schering Pharma AG as a provider for structural biology services.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |